Citations

Clear

258 citation(s) found for "Ge, Tian".

Neuroimmune interaction in seizures and epilepsy: focusing on monocyte infiltration
Bosco, Dale B. , Tian, Dai‐Shi , Wu, Long‐Jun , Wu, Long-Jun , Tian, Dai-Shi

Mayo Clinic

The FEBS Journal | May 30, 2020 | Volume: 287 | Issue: 22 | Pages: 4822-4837

10.1111/febs.15428 | PMID 32473609 Get It

Epilepsy is a major neurological condition that affects millions of people globally. While a number of interventions have been developed to mitigate this condition, a significant number of patients are refractory to these treatments. Consequently, other avenues of research are needed. One such avenue is modulation of the immune system response to this condition, which has mostly focused on microglia, the resident immune cells of the central nervous system (CNS). However, other immune cells can impact neurological conditions, principally blood‐borne monocytes that can infiltrate into brain parenchyma after seizures. As such, this review will first discuss how monocytes can be recruited to the CNS and how they can be distinguished from there immunological cousins, microglia. Then, we will explore what is known about the role monocytes have within seizure pathogenesis and epilepsy. Considering how little is known about monocyte function in seizure‐ and epilepsy‐related pathologies, further studies are warranted that investigate infiltrated blood‐borne monocytes as a potential therapeutic target for epilepsy treatment.
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
Zhang, Tian , Watt, Colleen, Wen, Yujia , Shergill, Ardaman , Vaishampayan, Ulka N. , George, Daniel J. , Vaishampayan, Ulka , Ballman, Karla V. , Choudhury, Atish D. , Chen, Ronald C. , Zemla, Tyler , Emamekhoo, Hamid , Morris, Michael J. , George, Daniel J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS5100-TPS5100

10.1200/jco.2020.38.15_suppl.tps5100 Get It

TPS5100 Background: First-line treatment of mRCC has rapidly changed to include IPI-NIVO or CABO, with clinical benefit of each based on the Checkmate 214 and CABOSUN (A031203) trials. Combination immunotherapy with VEGF therapies has shown benefit over sunitinib in the JAVELIN 101 and KEYNOTE 426 trials. It is yet unclear which patients (pts) benefit most from combination immunotherapy-VEGF inhibitors, and the optimal sequence of drugs. Methods: In an adaptive, randomized, multicenter phase 3 trial (Alliance A031704, PDIGREE), pts start treatment with induction IPI 1 mg/kg and NIVO 3 mg/kg intravenously (IV) once every 3 weeks. Key inclusion criteria include clear cell mRCC, International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk, Karnofsky performance status > 70, and no prior treatments for mRCC. Based on 3-month radiographic assessment (after completing IPI-NIVO combination), pts with complete responses (CR) undergo maintenance NIVO 480 mg IV every 4 weeks; pts with progression of disease (PD) switch to CABO 60 mg oral daily; pts with non-CR/non-PD are randomized to NIVO 480 mg IV every 4 weeks versus NIVO 480 mg IV every 4 weeks with CABO 40 mg oral daily. Randomization is stratified by IMDC risk criteria and presence of bone metastases. The primary endpoint of the study is overall survival (OS). We hypothesize that 3-year OS will improve to 70% for NIVO-CABO compared to 60% for NIVO alone; to achieve 85% power with a two-sided alpha of 0.05 and exponential distribution, 696 patients will be randomized. Accounting for 30% patients with either CR or PD, and 5% dropout from toxicity, up to 1046 pts will be enrolled. Key secondary endpoints include progression-free survival, 12-month CR rate, overall response rate based on RECIST 1.1 and irRECIST criteria, and toxicity profiles. Quality of life will be assessed based on the FKSI-19, PROMIS-fatigue, and EQ5D-5L questionnaires. Biomarkers associated with CR, tissue-based and plasma-based biomarkers will be assessed. Updated enrollment through May 2020 will be presented. Clinical trial information: NCT03793166 .
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia ( CLL ) and monoclonal B‐cell lymphocytosis beyond the CLL internat
Kleinstern, Geffen , O’Brien, Daniel R. , Tian, Shulan , Kabat, Brian, Rabe, Kari G. , Yan, Huihuang , Vachon, Celine M. , Call, Timothy G. , Bruins, Laura A., Campos, Cecília Bonolo de , Leis, José F., Shanafelt, Tait D. , Ding, Wei , Braggio, Esteban , Kabat, Brian F, Chaffee, Kari G. , Norman, Aaron D. , Boddicker, Nicholas J, Parikh, Sameer A , Bruins, Laura, Bonolo de Campos, Cecilia, Ding, Wei , Cerhan, James R , Shanafelt, Tait D , Braggio, Esteban , Li, Xing , Vachon, Celine M. , Boddicker, Nicholas , Parikh, Sameer A. , Cerhan, James R. , Kay, Neil E. , Slager, Susan L.

Mayo Clinic

American Journal of Hematology | April 12, 2020 | Volume: 95 | Issue: 8 | Pages: 906-917

10.1002/ajh.25831 | PMID 32279347 Get It

Abstract Next‐generation sequencing identified about 60 genes recurrently mutated in chronic lymphocytic leukemia (CLL). We examined the additive prognostic value of the total number of recurrently mutated CLL genes (i.e., tumor mutational load [TML]) or the individually mutated genes beyond the CLL international prognostic index (CLL‐IPI) in newly diagnosed CLL and high‐count monoclonal B‐cell lymphocytosis (HC MBL). We sequenced 59 genes among 557 individuals (112 HC MBL/445 CLL) in a multi‐stage design, to estimate hazard ratios (HR) and 95% confidence intervals (CI) for time‐to‐first treatment (TTT), adjusted for CLL‐IPI and sex. TML was associated with shorter TTT in the discovery and validation cohorts, with a combined estimate of continuous HR = 1.27 (CI:1.17‐1.39, P = 2.6 × 10 −8 ; c ‐statistic = 0.76). When stratified by CLL‐IPI, the association of TML with TTT was stronger and validated within low/intermediate risk (combined HR = 1.54, CI:1.37‐1.72, P = 7.0 × 10 −14 ). Overall, 80% of low/intermediate CLL‐IPI cases with two or more mutated genes progressed to require therapy within 5 years, compared to 24% among those without mutations. TML was also associated with shorter TTT in the HC MBL cohort (HR = 1.53, CI:1.12‐2.07, P = .007; c ‐statistic = 0.71). TML is a strong prognostic factor for TTT independent of CLL‐IPI, especially among low/intermediate CLL‐IPI risk, and a better predictor than any single gene. Mutational screening at early stages may improve risk stratification and better predict TTT.
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Ren, Yingxue , Cherukuri, Yesesri , Wickland, Daniel P. , Sarangi, Vivekananda , Tian, Shulan , Carter, Jodi M. , Mansfield, Aaron S. , Block, Matthew S. , Knutson, Keith L. , Lin, Yi , Asmann, Yan W. , Mansfield, Aaron S , Lin, Yi , Carter, Jodi , Sherman, Mark E. , Knutson, Keith L.

Mayo Clinic

OncoImmunology | April 1, 2020 | Volume: 9 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1744947 | PMID 32523802 Get It

The genetic architecture of the human cerebral cortex
Grasby, Katrina L. , Jahanshad, Neda , Painter, Jodie N. , Colodro‐Conde, Lucía , Bralten, Janita , Hibar, Derrek P. , Lind, Penelope A. , Pizzagalli, Fabrizio , Ching, Christopher R. K. , McMahon, Mary , Shatokhina, Natalia , Zsembik, Leo , Thomopoulos, Sophia I. , Zhu, Alyssa H. , Strike, Lachlan T. , Alhusaini, Saud , Almeida, Marcio , Amlien, Inge K. , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J. , Bernard, Manon , Brouwer, Rachel M. , Buimer, Elizabeth E.L. , Bürger, Christian, Cannon, Dara M. , Chen, Qiang , Cheung, J. , Couvy‐Duchesne, Baptiste , Dale, Anders M. , Dalvie, Shareefa , Araujo, Tânia Kawasaki de , Zubicaray, Greig I. de , Zwarte, Sonja M. C. de , Braber, Anouk den , Doan, Nhat Trung , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Erk, Susanne , Fan, Chun Chieh , Fedko, Iryna O. , Foley, Sonya , Fukunaga, Masaki , Ge, Tian , Giddaluru, Sudheer, Goldman, Aaron L. , Green, Melissa J. , Groenewold, Nynke A. , Grotegerd, Dominik , Gurholt, Tiril P. , Hansell, Narelle K. , Harris, Mathew A., Harrison, Marc , Haswell, Courtney C. , Hauser, Michael A. , Heslenfeld, Dirk J., Ho, New Fei , Hoehn, David , Holleran, Laurena , Hottenga, Jouke‐Jan , Jansen, Iris E. , Jockwitz, Christiane , Karama, Sherif , Kasperavičiūtė, Dalia , Kaufmann, Tobias , Kelly, Sinéad, Kikuchi, Masataka , Klein, Marieke , Knapp, Michael , Knodt, Annchen R. , Krämer, Bernd , Lancaster, T. , Lewis, Lindsay B. , Mathias, Samuel R. , Melzer, Tracy R. , Milaneschi, Yuri , Mirza‐Schreiber, Nazanin , Moreira, José C.V. , Mühleisen, Thomas W. , Müller‐Myhsok, Bertram , Najt, Pablo , Nakahara, Soichiro , Orfanos, Dimitri Papadopoulos , Pitcher, Toni L. , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R. , Redlich, Ronny , Repple, Jonathan , Riedel, Brandalyn C. , Risacher, Shannon L. , Rocha, Cristiane S. , Salminen, Lauren E. , Saremi, Arvin , Schlag, Fenja, Schmaal, Lianne , Secolin, Rodrigo , Shapland, Chin Yang , Shumskaya, Elena , Sønderby, Ida E. , Sprooten, Emma , Tansey, Katherine E. , Teumer, Alexander , Thalamuthu, Anbupalam , Tordesillas‐Gutiérrez, Diana , Turner, Jessica A. , Uhlmann, Anne , Meer, Dennis van der , Donkelaar, Marjolein M. J. van , Eijk, Liza van , Haren, Neeltje E.M. van , Tol, Marie‐José van , Walton, Esther , Wang, Mingyuan, Wardlaw, Joanna M. , Wen, Wei , Whelan, Christopher D. , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing , Yasuda, Clarissa Lin , Zaremba, Dario , Zhang, Zuo , Zwiers, Marcel P. , Artiges, Éric , Assareh, Amelia A., Ayesa‐Arriola, Rosa , Belger, Ayşenil , Brandt, Christine L., Brown, Gregory G. , Cichon, Sven , Curran, Joanne E. , Davies, Gareth E., Degenhardt, Franziska , Dennis, Michelle F. , Dietsche, Bruno, Doherty, Colin P. , Espiritu, Ryan, Gowland, Penny , Häusler, Alexander N. , Heindel, Walter , Ho, Beng‐Choon , Holsboer, Florian , Hosten, Norbert , Jang, MiHyun , Jansen, Andreas , Koops, Sanne, Krug, Axel , Lim, Kelvin O. , Luykx, Jurjen J. , Mather, Karen A. , Mattay, Venkata S. , Son, Jacqueline Mayoral-van , McEwen, Sarah , Melle, Ingrid , Morris, Derek W. , Nöthen, Markus M. , OʼLeary, Daniel S. , Martinot, Marie‐Laure Paillère , Preda, Adrian , Quinlan, Erin Burke , Rasser, Paul E. , Reppermund, Simone , Steen, Vidar M. , Tooney, Paul A. , Torres, Fábio R. , Veltman, Dick J. , Voyvodic, James , White, Tonya , Yamamori, Hidenaga , Adams, Hieab H.H. , Bis, Joshua C. , Debette, Stéphanie , DeCarli, Charles , Fornage, Myriam , Guðnason, Vilmundur , Hofer, Edith , Ikram, M. Arfan , Longstreth, W.T. , Roshchupkin, Gennady V. , Satizábal, Claudia L. , Schmidt, Reinhold, Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Alvim, Marina K. M. , Ames, David, Anderson, Tim , Blangero, John , Brodaty, Henry , Brunner, Han G. , Buckner, Randy L. , Buitelaar, Jan K. , Cairns, Murray J. , Calhoun, Vince D. , Caseras, Xavier , Caspers, Svenja , Cavalleri, Gianpiero L. , Cendes, Fernando , Corvin, Aiden , Crespo‐Facorro, Benedicto , Dalrymple‐Alford, John C. , Geus, Eco J. C. de , Deary, Ian J. , Delanty, Norman, Depondt, Chantal, Desrivières, Sylvane , Donohoe, Gary , Fisher, Simon E. , Flor, Herta , Forstner, Andreas J. , Francks, Clyde , Franke, Barbara , Glahn, David C., Gruber, Oliver , Hariri, Ahmad R. , Hartman, Catharina A. , Hashimoto, Ryota , Heinz, Andreas , Hillegers, Manon H. J. , Hoekstra, Pieter J. , Hong, L. Elliot , Pol, Hilleke E. Hulshoff , Jönsson, Erik G. , Kahn, René S. , Kennedy, Martin A. , Kircher, Tilo , Hellard, Stéphanie Le , Loughland, Carmel M. , Martinot, Jean‐Luc , McMahon, Katie L. , Meyer‐Lindenberg, Andreas , Michie, Patricia T. , Morey, Rajendra A. , Mowry, Bryan , Nyberg, Lars , Oosterlaan, Jaap , Pantelis, Christos , Pausová, Zdenka , Penninx, Brenda W.J.H. , Polderman, Tinca J. C. , Posthuma, Daniëlle , Rowland, Laura M. , Sachdev, Perminder S. , Sämann, Philipp G. , Schall, Ulrich , Schumann, Günter , Scott, Rodney J. , Sim, Kang , Smoller, Jordan W., Sommer, Iris E. , Pourcain, Beaté St , Stein, Dan J. , Ent, Dennis van ‘t , Völzke, Henry , Weber, Bernd , Weinberger, Daniel R. , Wright, Margaret J. , Zhou, Juan , Thompson, Paul M. , Medland, Sarah E. , Seppi, Klaus , Duijn, Cornelia M. van , Jicha, Gregory A. , Vernooij, Meike W. , Mishra, Aniket , Saba, Yasaman , Shenkman, Elizabeth , Ghanbari, Mohsen , Knol, Maria J. , Witte, A. Veronica , Kremen, Sarah , DeCarli, Charles , McMahon, Mary Agnes B , Zsembik, Leo C P , Agartz, Ingrid , Almeida, Marcio A A , Amlien, Inge K , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J , Atkins, Joshua R , Bernard, Manon , Brouwer, Rachel M , Buimer, Elizabeth E L , Chen, Qiang , Cheung, Joshua W , Couvy-Duchesne, Baptiste , Dale, Anders M , de Araujo, Tânia K , de Zubicaray, Greig I , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Fedko, Iryna O , Ford, Judith M , Fukunaga, Masaki , Garrett, Melanie E , Green, Melissa J , Grotegerd, Dominik , Gurholt, Tiril P , Gutman, Boris A , Hansell, Narelle K , Harris, Mathew A , Harrison, Marc B , Haswell, Courtney C , Hauser, Michael , Herms, Stefan , Hoehn, David , Hoffmann, Per , Holleran, Laurena , Hoogman, Martine , Hottenga, Jouke-Jan , Ikeda, Masashi , Janowitz, Deborah , Jansen, Iris E , Jia, Tianye , Jockwitz, Christiane , Kanai, Ryota , Karama, Sherif , Kaufmann, Tobias , Kikuchi, Masataka , Klein, Marieke , Knodt, Annchen R , Krämer, Bernd , Lee, Phil H , Lewis, Lindsay B , Lopes-Cendes, Iscia , Luciano, Michelle , Macciardi, Fabio , Marquand, Andre F , Melzer, Tracy R , Mirza-Schreiber, Nazanin , Moreira, Jose C V , Mühleisen, Thomas W , Najt, Pablo , Olde Loohuis, Loes M , Orfanos, Dimitri Papadopoulos , Pearson, John F , Pitcher, Toni L , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R , Reinbold, Céline S , Repple, Jonathan , Richard, Geneviève , Riedel, Brandalyn C , Rocha, Cristiane S , Mota, Nina Roth , Salminen, Lauren , Saremi, Arvin , Saykin, Andrew J , Schlag, Fenja , Schofield, Peter R , Secolin, Rodrigo , Shapland, Chin Yang , Shen, Li , Shin, Jean , Shumskaya, Elena , Sprooten, Emma , Thalamuthu, Anbupalam , Turner, Jessica A , Vallerga, Costanza Ludovica , van Eijk, Liza , van Erp, Theo G M , van Haren, Neeltje E M , van Rooij, Daan , van Tol, Marie-José , Veldink, Jan H , Verhoef, Ellen , Walton, Esther , Wang, Mingyuan , Wang, Yunpeng , Wardlaw, Joanna Marguerite , Wen, Wei , Westlye, Lars T , Witt, Stephanie H , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing Qin , Yasuda, Clarissa L , Zhang, Zuo , Artiges, Eric , Ayesa-Arriola, Rosa , Belger, Aysenil , Cichon, Sven , Curran, Joanne E , Dennis, Michelle F , Djurovic, Srdjan , Doherty, Colin P , Garijo, Daniel , Gowland, Penny A , Green, Robert C. , Häusler, Alexander N , Ho, Beng-Choon , Hoffmann, Wolfgang U , Holsboer, Florian , Homuth, Georg , Hosten, Norbert , Jack, Clifford R , Jang, MiHyun , Jansen, Andreas , Krug, Axel , Lim, Kelvin O , Luykx, Jurjen J , Mathalon, Daniel H , Mattay, Venkata S , McEwen, Sarah C , Melle, Ingrid , Morris, Derek W , Mueller, Bryon A. , Nordvik, Jan E , Nöthen, Markus M , O'Leary, Daniel S , Preda, Adrian , Rasser, Paul E , Ratnakar, Varun , Steen, Vidar M , Torres, Fábio R , Veltman, Dick J , Voyvodic, James T , Whelan, Robert , Yamamori, Hidenaga , Adams, Hieab H H , López, Oscar L. , Mazoyer, Bernard , Mosley, Thomas H. , Satizabal, Claudia L , Seshadri, Sudha , Alvim, Marina K M , Anderson, Tim J , Andreassen, Ole A , Bastin, Mark E , Beckham, Jean C , Boomsma, Dorret I , Brodaty, Henry , Buitelaar, Jan K , Bustillo, Juan R , Cahn, Wiepke , Cairns, Murray J , Calhoun, Vince D. , Carr, Vaughan J , Cavalleri, Gianpiero L , Corvin, Aiden , Crespo-Facorro, Benedicto , Dalrymple-Alford, John C , Dannlowski, Udo , de Geus, Eco J C , Depondt, Chantal , Desrivières, Sylvane , Donohoe, Gary , Espeseth, Thomas , Fisher, Simon E , Flor, Herta , Francks, Clyde , Franke, Barbara , Gollub, Randy L , Håberg, Asta K , Hartman, Catharina A , Henskens, Frans A , Hillegers, Manon H J , Hoekstra, Pieter J , Holmes, Avram J , Hulshoff Pol, Hilleke E , Jönsson, Erik G , Kennedy, Martin A , Kircher, Tilo T J , Kwok, John B J , Le Hellard, Stephanie , Martin, Nicholas G , McMahon, Katie L , Meyer-Lindenberg, Andreas , Michie, Patricia T , Morey, Rajendra A , Mowry, Bryan , Oosterlaan, Jaap , Ophoff, Roel A , Pantelis, Christos , Pausova, Zdenka , Penninx, Brenda W J H , Polderman, Tinca J C , Posthuma, Danielle , Rietschel, Marcella , Roffman, Joshua L , Sachdev, Perminder S , Schall, Ulrich , Sim, Kang , Sommer, Iris E , St Pourcain, Beate , Stein, Dan J , Toga, Arthur W , Trollor, Julian N , Van der Wee, Nic J A , van 't Ent, Dennis , Walter, Henrik , Weber, Bernd , Weinberger, Daniel R , Wright, Margaret J , Zhou, Juan , Stein, Jason L , Thompson, Paul M , Medland, Sarah E , de Zwarte, Sonja M C , Ching, Christopher R K , Thomopoulos, Sophia I , Cendes, Fernando , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Seppi, Klaus , Hashimoto, Ryota , Jicha, Gregory A , Ge, Tian , Kremen, Sarah , Agartz, Ingrid , Alnæs, Dag , Ashley‐Koch, Allison E. , Bülow, Robin , Bürger, Christian, Chakravarty, M. Mallar , Dohm, Katharina , Lam, Max , Lett, Tristram A. P. , Lopes‐Cendes, Íscia , Nho, Kwangsik T. , Pütz, Benno , Rashid, Faisal M. , Saykin, Andrew J. , Schofield, Peter R. , Shen, Li , Veldink, Jan H. , Witt, Stephanie H. , Gil, Yolanda , Jack, Clifford R. , Kimbrel, Nathan A. , Kolskår, Knut K. , Matthews, Sarah , Nauck, Matthias A. , Opel, Nils , Pike, G. Bruce , Launer, Lenore J. , Mosley, Thomas H. , Seshadri, Sudha , Yang, Qiong , Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Andreassen, Ole A. , Vásquez, Alejandro Arias , Bastin, Mark E. , Baune, Bernhard , Fernández, Guillén , Grabe, Hans Jörgen , Hopkins, William Donald , Jernigan, Terry L. , Kochunov, Peter V , Kwok, John B. , Martin, Nicholas G. , McDonald, Colm , Ophoff, Roel A. , Paus, Tomáš , Sisodiya, Sanjay , Smoller, Jordan W. , Toga, Arthur W. , Walter, Henrik , Stein, Jason L.

Mayo Clinic

Science | March 19, 2020 | Volume: 367 | Issue: 6484 | Pages: No page available

10.1126/science.aay6690 | PMID 32193296 Get It

INTRODUCTION The cerebral cortex underlies our complex cognitive capabilities. Variations in human cortical surface area and thickness are associated with neurological, psychological, and behavioral traits and can be measured in vivo by magnetic resonance imaging (MRI). Studies in model organisms have identified genes that influence cortical structure, but little is known about common genetic variants that affect human cortical structure. RATIONALE To identify genetic variants associated with human cortical structure at both global and regional levels, we conducted a genome-wide association meta-analysis of brain MRI data from 51,665 individuals across 60 cohorts. We analyzed the surface area and average thickness of the whole cortex and 34 cortical regions with known functional specializations. RESULTS We identified 369 nominally genome-wide significant loci ( P < 5 × 10 −8 ) associated with cortical structure in a discovery sample of 33,992 participants of European ancestry. Of the 360 loci for which replication data were available, 241 loci influencing surface area and 66 influencing thickness remained significant after replication, with 237 loci passing multiple testing correction ( P < 8.3 × 10 −10 ; 187 influencing surface area and 50 influencing thickness). Common genetic variants explained 34% (SE = 3%) of the variation in total surface area and 26% (SE = 2%) in average thickness; surface area and thickness showed a negative genetic correlation ( r G = −0.32, SE = 0.05, P = 6.5 × 10 −12 ), which suggests that genetic influences have opposing effects on surface area and thickness. Bioinformatic analyses showed that total surface area is influenced by genetic variants that alter gene regulatory activity in neural progenitor cells during fetal development. By contrast, average thickness is influenced by active regulatory elements in adult brain samples, which may reflect processes that occur after mid-fetal development, such as myelination, branching, or pruning. When considered together, these results support the radial unit hypothesis that different developmental mechanisms promote surface area expansion and increases in thickness. To identify specific genetic influences on individual cortical regions, we controlled for global measures (total surface area or average thickness) in the regional analyses. After multiple testing correction, we identified 175 loci that influence regional surface area and 46 that influence regional thickness. Loci that affect regional surface area cluster near genes involved in the Wnt signaling pathway, which is known to influence areal identity. We observed significant positive genetic correlations and evidence of bidirectional causation of total surface area with both general cognitive functioning and educational attainment. We found additional positive genetic correlations between total surface area and Parkinson’s disease but did not find evidence of causation. Negative genetic correlations were evident between total surface area and insomnia, attention deficit hyperactivity disorder, depressive symptoms, major depressive disorder, and neuroticism. CONCLUSION This large-scale collaborative work enhances our understanding of the genetic architecture of the human cerebral cortex and its regional patterning. The highly polygenic architecture of the cortex suggests that distinct genes are involved in the development of specific cortical areas. Moreover, we find evidence that brain structure is a key phenotype along the causal pathway that leads from genetic variation to differences in general cognitive function. Identifying genetic influences on human cortical structure. ( A ) Measurement of cortical surface area and thickness from MRI. ( B ) Genomic locations of common genetic variants that influence global and regional cortical structure. ( C ) Our results support the radial unit hypothesis that the expansion of cortical surface area is driven by proliferating neural progenitor cells. ( D ) Cortical surface area shows genetic correlation with psychiatric and cognitive traits. Error bars indicate SE. IMAGE CREDITS: (A) K. COURTNEY; (C) M. R. GLASS
Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.
Fanburg–Smith, Julie C. , Kayton, Mark L. , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Scharschmidt, Thomas J. , Sorger, Joel, Tian, Jing , Terezakis, Stephanie , Wang, Dian , Zambrano, Eduardo , Black, Jennifer O. , Weiss, Aaron R. , Chi, Yueh‐Yun , Chen, Yen‐Lin , Choy, Edwin , Davis, Jessica L. , Hawkins, Douglas S. , Randall, R. Lor , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11002-11002

10.1200/jco.2019.37.15_suppl.11002 Get It

11002 Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor with activity in advanced soft tissue sarcoma. ARST1321 is a phase II study designed to compare the near complete pathologic response rate (≥ 90% necrosis) of preoperative chemoradiation +/- pazopanib in children and adults with intermediate/high risk chemotherapy-sensitive NRSTS. Methods: ARST1321 is a jointly designed COG and NRG Oncology study opened to enrollment in July 2014. Eligible adult (≥18 years) and pediatric ( < 18 years) patients with unresected, newly diagnosed truncal/extremity NRSTS were enrolled into the Chemotherapy Cohort ( > 5 cm, grade 2/3, protocol-designated chemotherapy-sensitive histology). Following a dose-finding phase, patients were randomized to receive (Regimen A) or not receive (Regimen B) pazopanib ( < 18 years: 350 mg/m2/day; ≥ 18 years: 600 mg/day) in combination with ifosfamide (7.5 gm/m2/cycle) and doxorubicin (75 mg/m2/cycle) + 45 Gy preoperative RT followed by primary resection at week 13, then adjuvant chemotherapy. Results: As of June 30, 2018, 81 eligible patients were enrolled and randomized. Week 13 response is available for 42 patients (60% of expected information). The rate of ≥ 90% pathologic necrosis was 58.3% for Regimen A and 22.2% for Regimen B. Based on the significance level of 0.081 (for the second efficacy analysis with overall one-sided significance level of 0.20, power of 0.80, and O’Brien-Fleming-type cumulative error spending function), the 83.8% confidence interval for the difference was between 16.5% and 55.8%. At this predetermined interim analysis, the efficacy bound was crossed indicating that Regimen A is more efficacious than Regimen B. Given these findings, enrollment was stopped. Grade 3/4 toxicities were 73.8% for Regimen A and 29% for Regimen B with neutropenia, thrombocytopenia and febrile neutropenia being the most common toxicities. Conclusions: The rate of near complete pathologic response was significantly greater with the addition of pazopanib to preoperative chemoradiation in children and adults with intermediate/high risk NRSTS. The comparison of survival outcomes requires longer follow-up. Clinical trial information: NCT02180867.
A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).
Tap, William D. , Tine, Brian Andrew Van, Livingston, Michael B. , Agulnik, Mark , Cooney, Matthew M. , Pennock, Gregory , Somaiah, Neeta , Dang, Long H. , Tian, G. Gary, Okuno, Scott H. , Loizos, Nick, Nippgen, Johannes, Elias, Anthony , Chmielowski, Bartosz , Brenner, Andrew Jacob , Jones, Robin L. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: TPS10099-TPS10099

10.1200/jco.2012.30.15_suppl.tps10099 Get It

TPS10099 Background: PDGFRα is a receptor commonly overexpressed in STS. Olaratumab is a fully human IgG1 MAb which specifically binds to human PDGFRα and blocks PDGFR-mediated signaling pathways. Olaratumab demonstrated significant tumor inhibition as a monotherapy and in combination with standard chemotherapy in preclinical human sarcoma xenograft models. A Phase 1b/2 clinical trial for patients with advanced or metastatic STS is currently enrolling patients in 9 sites across the United States; approximately 45 patients have been randomized. Methods: In Phase 1b, patients received olaratumab (15 mg/kg) via intravenous infusion on Days 1 and 8 of each 21-day cycle and D (75 mg/m²) 1 hour after olaratumab on Day 1. Phase 1b was completed without encountering dose-limiting toxicities; enrollment into Phase 2 has begun. The primary endpoint of the Phase 2 portion is to compare progression-free survival in patients with advanced STS when treated with D plus olaratumab versus D alone. Planned enrollment goal for Phase 2 is 130 patients. Patients are required to be ≥ 18 years old with ECOG 0-2, have appropriate organ function and histologically confirmed, measurable, and advanced STS. There is no restriction on the number of prior therapies. Patients are randomized 1:1 to either D plus olaratumab (Arm A) at same dose/schedule as in Phase 1b or D alone (Arm B). All patients can receive dexrazoxane. Upon completion of 8 cycles, patients in Arm A continue with olaratumab monotherapy. Patients in Arm B who develop disease progression during or after treatment can subsequently receive olaratumab monotherapy. Patients are stratified to treatment arms according to PDGFRα expression (positive vs. negative), number of previous lines of treatment, sarcoma subtype, and ECOG performance status. Response assessment occurs every 6 weeks. Exploratory analyses include biomarkers of olaratumab pharmacodynamic activity including PDGF ligands, PDGFR downstream molecules, VEGF, and changes in vascularity of tumor specimens.
Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: A multivariate analysis of three Gynecologic Oncology Group trials
Moore, Dan H. , Tian, Chunqiao , Monk, Bradley J. , Long, Harry J., Omura, Gaku

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 25 | Issue: 18_suppl | Pages: 5534-5534

10.1200/jco.2007.25.18_suppl.5534 Get It

5534 Purpose: A number of patients with advanced/recurrent cervical cancer do not respond to cisplatin-based chemotherapy. A pool analysis of three published phase III GOG studies was undertaken to identify the predictive factors and develop a model predictive of (non-) response to chemotherapy. Methods: The study population consisted of patients who received single-agent cisplatin or a cisplatin-containing combination in GOG protocols 110, 169 and 179. Prognostic variables (age, race, performance status, stage, histology, grade, disease site, prior chemotherapy—with primary radiation, time to recurrence, single-agent versus combination) were analyzed and multivariate analysis was conducted to identify factors independently predictive of response and survival. These analyses were used to establish a predictive model. Results: 816 patients were evaluable for response. In addition to single-agent treatment, multivariate analysis identified six factors (age, African-American, PS > 0, pelvic disease, prior radiosensitizer, recurrence ≤ one year) independently predictive of poor response. Those factors, but not age and African-American, were also independently associated with increased risk of death. 428 patients treated with a cisplatin- containing combination were classified into three risk groups based on the total number of risk factors (low risk: 0–1 factor; mid risk: 2–3 factors; high risk: 4–5 factors). Patients with 4–5 of risk factors were predicted to have a treatment response of only 13% (observed 10%), and median progression-free and overall survival of PFS of 2.8 months and 5.5 months, respectively. This subgroup of patients consist ∼14% of the target population in clinical practice. The predictive model was externally validated using GOG protocol 149 data that were not used for model development and further supported the predictive accuracy. Conclusions: High risk patients should be directed to non-cisplatin chemotherapy or investigational trials. No significant financial relationships to disclose.
Association of Dual Decline in Memory and Gait Speed With Risk for Dementia Among Adults Older Than 60 Years
Tian, Qu , Resnick, Susan M. , Yaffe, Kristine , Jónsson, Pálmi V. , Grande, Giulia , Welmer, Anna‐Karin , Bandinelli, Stefania , Rosano, Caterina , Studenski, Stephanie A. , Ferrucci, Luigi , Ferrucci, Luigi , Mielke, Michelle M. , Launer, Lenore J. , Laukka, Erika J. , Cherubini, Antonio , Kritchevsky, Stephen B. , Simonsick, Eleanor Marie

Mayo Clinic

JAMA Network Open | February 21, 2020 | Volume: 3 | Issue: 2 | Pages: e1921636

10.1001/jamanetworkopen.2019.21636 | PMID 32083691 Get It